1 / 29

eu-openscreen.eu

www.eu-openscreen.eu. Initiative for a European Research Infrastructure of Open Screening Platforms for Chemical Biology. Partners of preparatory phase project. EU-OPENSCREEN builds on national networks in 14 European countries. NOR-OPENSCREEN Swedish Chemical Biology Consortium

enoch
Download Presentation

eu-openscreen.eu

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. www.eu-openscreen.eu Initiative for a European Research Infrastructure of OpenScreening Platforms for Chemical Biology

  2. Partners of preparatory phase project EU-OPENSCREEN builds on national networks in 14 European countries. • NOR-OPENSCREEN • Swedish Chemical Biology Consortium • Drug Discovery and Chemical Biology network Finnland • Danish Chemical Biology Initiative • Dutch Chemical Library Program • ChemBioNet Germany • POL-OPENSCREEN • CZ-OPENSCREEN and Czech ChemGen • Austrian PLACEBO • Spanish ChemBioBank • French Chimiothèque Nationale, Réseau Nationale de Criblage, FR-OPENSCREEN • Romanian Chemical Biology Net • Flemish Network on Chemical Biology • Collezione Nazionale dei Composti Chimici e Centro Screening Currentpartners Associated members CoordinationCentreat FMP Berlin

  3. Chemical Biology Investigation of biological systems using chemical tools Infrastructures for the European Research Area 23/09/2014 Page 3 3

  4. Infrastructures for the European Research Area Biological & Medical Sciences Understanding the principles of life Physics Social Sciences “Modern research in all scientific fields requires expensive instruments and resources, and is characterised by a continuous interplay between new scientific challenges and our technical responses to them.“ (ESFRI report) Astronomy Information Technology

  5. European Strategy Forum on Research Infrastructures (ESFRI) Set up in 2002 by the Competitiveness Council. Meeting of Senior Representatives for informal consultations on strategic issues related to research infrastructures (RI). Independent from the European Commission. 2004: Mandate to develop a European Strategic Roadmap for Research Infrastructures - to describe the needs for the next 10 to 20 years - to identify vital new European research infrastructures. Infrastructures for the European Research Area

  6. ESFRI Roadmap Published in October 2006, updated in 2008 and 2010. Will be used to facilitate decision-making by member states and EC. Will not prioritise or decide on funding and locations. Four areas: Physical Sciences and Engineering (PSE), Biological and Medical Sciences (BMS), Social Sciences and Humanities (SSH), Environment (ENV). Total: 48 ESFRI infrastructures.

  7. ESFRI BMS – Fields of Activity Biological Sciences Biological Resources & Production Systems Medical Sciences Bioinformatics Bio Banking & Molecular Resources Clinical Research Translational Medicine Functional Genomics in the Mouse Marine Biology StructuralBiology High Security Laboratories Chemical Biology (EU-OPENSCREEN) Imaging Systems Biology Ecosystems Microbial Resources

  8. ESFRI BMS – Fields of Activity Towards supporting an innovation chain without gaps • The EU-OPENSCREEN database will be linked to other biological databases through ELIXIR: BioMedBridges • Compounds with potential as drug candidates can be further developed through EATRIS and ECRIN • Cell-lines and animal models for bioprofiling of compounds are available through BBMRI and INFRAFRONTIER (BMS-RI) support • Natural products from MIRRI and EMBRC. MIRRI ANAEE ISBE

  9. EU-OPENSCREEN’s Mission • A pan-European infrastructure to... • accelerate the discovery of biologically active substances in all areas of the life sciences • facilitate transnational access to the most advanced technologies, chemical and biological resources, knowledge and expertise • advance the elucidation of the molecular mechanisms of complex biological processes • increase knowledge on the bio-activities of chemical substances, as well as the responses of biological systems to these substances • promote the availability of safe and efficacious chemical products for unmet needs in medicine, nutrition, agriculture, environment

  10. THE PREPARATORY PHASE PROJECT WP1 Management and coordination WP6 Governance structure WP7 Financial plan WP8 IPR issues Physical infrastructure WP9 Chemical Resources WP12 Chem& BioInformatics WP5 Strategy Advisory Board WP11 Technology Resources Steering Committee WP10 Biology Resources MGT Support Team WP2 Standardisation WP3 Training and education WP4 Dissemination and outreach

  11. Advisory Board Prof. Dr. Dr. Ernst Rietschel, former president of the Leibniz Association of Research centres (WGL), now acatech - National Academy of Science and Engineering(technology advisor for the German federal government) Prof. Dr. Ferran Sanz, Director of GRIB (Research Group in Biomedical Informatics) at IMIM (Municipal Institute for Medical Research) in Barcelona. He is also a member of the Scientific Advisory Board for the Innovative Medicines Initiative (IMI). Prof Dr. Serge Braun, scientific director of the Association Francaise contre les Myopathies (AFM) Dr. Steve Rees, VP of Screening Sciences,AstraZeneca (AZ)

  12. Expert Groups Chemical Diversity Group (WP9) chaired by Dr.Michael Foley, Broad Institute, USA Innovative Target & Assay Group (WP10) chaired by Sir Philip Cohen, UK Industrial Advisory Group (WP5) chaired by Dr.Philip Gribbon, European ScreeningPort; members: J. Everett (f. Pfizer), J. Kihlberg (Univ. Uppsala, former AZ), T. Langer (Prestwick), H-U. Stilz (SA) EU-OPENSCREEN Strategy Group (WP5) chaired by Dr.James Inglese, Chemical Genomics Centre, NIH, USA

  13. OBJECTIVES EU-OPENSCREEN´s objective is the development of novel research ‘tool’ compounds for all fields of the Life Sciences. • Tool compounds enable researchers to investigate molecular mechanisms of physiological and pathological processes, many of which can only be studied with these chemical ‘tools’ • Chemical tools complement methods of molecular biology, such as mutagenesis or RNA interference • All generated tools and data are made publically available to the scientific community Chemical keys for life’s locks Chemical compounds, such as this small molecule, can bind to cellular structures (e.g. proteins) and modulate their functions.

  14. A Chemical Biology Infrastructure Serving research in all Life Sciences No Life Without Chemistry Food Ecology VeterinaryMedicine Medicine Chemical Biology Basic Research Pest Control

  15. Service Portfolio EU-OPENSCREEN will provide services to support the development of tool compounds at all stages

  16. LAYOUT OF RI EU-OPENSCREEN integrates Europe´s expert resources and facilities into its unique concept of a knowledge-creating Chemical Biology Centreand supports all stages of tool development projects in an RI ‘open’ for external researchers. Biology Assays & Targets Chemistry Compounds meets Partner Sites User User Activity profiles Tool compounds Screening Technology Chemistry Services Compound Collection Database EU-OPENSCREEN-ERIC Project Management Training & Education CompoundProfiling Compound Management Service contracts

  17. UNIQUE ERIC ELEMENTS The European Chemical Biology Library ECBL will - be designed and built on the expert knowledge of European chemists - cover unbiased chemical diversity with an expected size of 200k to 300k compounds - be driven by the prospect of bioactivity, intellectual curiosity, uniqueness, and the goal of generating knowledge (not necessarily new chemical entities, NCEs) - be composed to optimally serve the community and its needs; will contain selections from academic chemistry labs, commercial collections, known drugs, natural products, environmentals, etc. - be quality controlled by approved standard method (LC-MS) - be fully profiled with a set of basic properties (biophysical, cellular cytotoxicity, antimicrobial) - be systematically profiled against hundreds of assays conducted by the network of screening centres.

  18. UNIQUE EUROPEAN ASSETS • The European Chemical Biology Database (ECBD) will be a web portal with powerful search and analysis capabilities: • contains validated output from screening centres in a public as well as pre-release environment. • supports curation, annotation and organization of data + metadata. • data deposition with flexible privacy model for rapid and safe dissemination and exploitation. Optional hold period of 18 months for data publication. • The broadest possible use of data through public accessibility and dissemination. Public data also freely available for complete download, redistribution. • High standards of security and traceability of IP (citable indexing of data points (EUOS, DOI or URL). Links to originator labs for primary raw unprocessed data. • Links to SAR (e.g. ChEMBL), Chemical Structure (e.g. PubChem), and Target (e.g. UniProt) resources. Links established with new NIH-funded BARD resource.

  19. Project Selection Projects are evaluated by external reviewers and implemented according to milestones along a defined timeline. Tool compound Validated chemical structure Extensive basic Bio-profile Bioactivity data from hundreds of assays

  20. BUDGET (LIMITED CAPACITY) Central costs (6 years) Shared funding ~ 27 m € (e.g. GDP-share) Project costs (6 years) Shared funding ~ 30 m € (e.g. GDP-share,cost ceiling) Shared funding of Member countries The required minimum budget for EU-OPENSCREEN is modest and shared between member countries. Service site upgrades National funding Office Upgrade 1 45 m€ already invested Upgrade 2 ECBL Upgrade 3 ECBD Upgrade 4 Training Upgrade 5

  21. BUDGET (FULL CAPACITY) Central costs (6 years) Shared funding ~ 27 M € (e.g. GDP-share) The required minimum budget for EU-OPENSCREEN is modest and shared between member countries. Project costs (6 years) Diversefundingsources ~ 60 m€ Users (research grants, in addition to EU-grants) Service site upgrades National funding EU-funding to users (research grants) Office EU-funding to EU-OPENSCREEN Upgrade 1 45 m€ already invested Upgrade 2 ECBL Upgrade 3 Shared funding of Member countries ECBD Upgrade 4 Training Upgrade 5

  22. ADDED VALUE • EU-OPENSCREEN´s ‘open’ character: large pool of external biologists and chemists provide wide range of expertise, assays and diverse compounds. Compounds Compounds Hit FR FR UK UK Spanish target DE DE Targets Targets ES ES French compound IT IT x x Without EU-OPENSCREEN: Limited chance of finding a hit against a target from local or national compound collections With EU-OPENSCREEN: European Scale Advantage: Exponential increase of the likelihood of finding a hit against a target from a national compound collection

  23. ADDED VALUE • EU-OPENSCREEN´s ‘open’ character: large pool of external biologists and chemists provide wide range of expertise, assays and diverse compounds. Compounds Compounds UK FR Hit FR DE Targets UK ES Spanish target DE IT Targets x ES French compound IT Without EU-OPENSCREEN: Limited chance of finding a hit against a target from local or national compound collections With EU-OPENSCREEN: European Scale Advantage: Exponential increase of the likelihood of finding a hit against a target from a national compound collection x

  24. IMPACT ON SCIENCE In the Life Sciences, large-scale open-access research consortia have already proven fundamental to breakthroughs in their fields. Weigelt (2009): “The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery.” EMBO Rep. 10: 941–945

  25. IMPACT ON DRUG DISCOVERY Public Sector Research Institutions (PSRI) contribute particularly to new NCEs and new indications. Stevens, A.J. et al., 2011, N ENGL J MED 364:535-541.

  26. TIMELINE Now in the 3rd year of its Preparatory Phase, EU-OPENSCREEN will initiate construction and operation in 2014-2015. Roadmap Preparation Interim Construction Operation • ESFRI Roadmap: ESFRI considers EU-OPENSCREEN as vital to the excellence of research and innovation in Europe and included it on the “European Roadmap of Research Infrastructures”. • Preparatory Phase (3 years): Preparation of a business plan describing in detail the mode of construction and operation. MoU signed. EU funding: 3.7 M€. • Interim Phase (1-1.5 years): ERIC application and approval. Institutional funding. • Construction Phase (1 year): Construction of infrastructure (existing and new sites). National funding. • Operation Phase: Active infrastructure with access for researchers. Diverse funding sources.

  27. CURRENT STATUS AND NEXT STEPS EU-OPENSCREEN was included on several national roadmaps and is now initiating negotiations with governments and funding organisations. • EU-OPENSCREEN in 3rd year of Preparatory Phase: Challenge before Construction and Operation Phases is the securing of (financial) commitment of member countries • Timelines of member countries vary: Transition Committee for the time between the end of the Preparatory Phase and the start of the Construction and Operation Phases will be formed • EU-OPENSCREEN included on several nationalRoadmaps • MoU document , financial plan, funding strategy, • draft ERIC statutes and draft Business Plan • already available On national Roadmap  start negotiations Decision expected in 2013 EU-OPENSCREEN – Executive Summary Page 27 August 2013

  28. Next Project & Stakeholder Meeting Tuesday, 19 Nov – Project Meeting 09:00-13:00 General Assembly meeting (project participants) 14:30-18:00 EU-OPENSCREEN outreach and synergies (invited guests) Interactions with representatives of other ESFRI infrastructures, JPI's and IMI´s European Lead Factory 19:30 EU-OPENSCREEN networking dinner Wednesday, 20 Nov – Stakeholder Meeting 09:30-16:00 EU-OPENSCREEN Science Day (open) - 3 presentations from EU-OPENSCREEN - 6 reports on flagship projects 13:00-16:00 Transition Committee Meeting (closed) Oslo Norway

  29. THE TEAM Thank you for your attention www.eu-openscreen.eu

More Related